Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents.
| Autor: | Maldonado-Rojas ADC; Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Universidad Popular Autónoma del Estado de Puebla (UPAEP), Mexico City, Puebla, Mexico., Zuarth-Vázquez JM; Internal Medicine Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Endocrinology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Uribe M; Gastroenterology and Obesity Unit. Medica Sur Clinic & Foundation, Mexico City, Mexico., Barbero-Becerra VJ; Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico. Electronic address: vbarberob@medicasur.org.mx. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of hepatology [Ann Hepatol] 2024 Mar-Apr; Vol. 29 (2), pp. 101182. Date of Electronic Publication: 2023 Dec 01. |
| DOI: | 10.1016/j.aohep.2023.101182 |
| Abstrakt: | Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by overweight/obesity, and the presence of type 2 diabetes mellitus is the most important criterion. We propose an independent disease perspective without exclusion criteria and with less heterogeneity and greater impact because, according to the National Health and Nutrition Survey (ENSANUT), in Mexico, 25 % of adults over 60 years of age suffer from diabetes, and 96 % of those over 50 years of age have abdominal obesity. Due to the impact of insulin resistance in the pathophysiology of MASLD, which results in damage to hepatocytes, this work aims to provide an overview of the action pathways of hypoglycemic agents such as glucagon-like-1 receptor agonist and peroxisome proliferator-activated receptor-gamma agonists, whose importance lies in the fact that they are currently undergoing phase 2 studies, as well as dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter type 2 inhibitors, which are undergoing phase 1 study trials. Competing Interests: Declaration of interests None. (Copyright © 2023 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|